3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Gastrointestinal
1
CNS
1
Conditions
Neoplasms
4
Lung Neoplasms
3
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Hematologic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Stomach Neoplasms
1
Sarcoma
1
Neuroblastoma
1
Lymphoproliferative Disorders
1
Glioma
1
Adenocarcinoma of Lung
1
Interventions
Temozolomide
16
Irinotecan
13
Cyclophosphamide
11
dinutuximab
9
naxitamab
7
Vincristine
7
Carboplatin
6
sargramostim
5
Melphalan
5
Granulocyte-Macrophage Colony-Stimulating Factor
5
Etoposide
5
fludarabine
4
Topotecan
4
Thiotepa
4
Eflornithine
4
Doxorubicin
4
Cisplatin
4
etoposide phosphate
3
Zoledronic Acid
3
Specimen Handling
3
Isotretinoin
3
Granulocyte Colony-Stimulating Factor
3
saponin QA-21V1
2
lutetium Lu 177 dotatate
2
aldesleukin
2
Vorinostat
2
Stem Cell Transplantation
2
Radiation
2
Platinum
2
Mesna
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neuroblastoma
×
capmatinib
×
Clear all
NCT06988475
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled